Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Scientific American
|
July 16, 2024
Why We Trust Lies
James Weatherall, Cailin O'Connor
Journal of the American Medical Informatics Association : JAMIA
|
March 27, 2018
The Tendril Plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials
Martin Karpefors, James Weatherall
Drug Discovery Today
|
January 10, 2026
Generative AI in pharmaceutical R&D: From large language models to AI agents to regulation
James Weatherall, Chris Meier,
Current Medical Research and Opinion
|
October 22, 2016
Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine
James Weatherall, Lisa Bloudek, Sarah Buchs
Journal of Medical Economics
|
June 24, 2020
The relative efficiency of schizophrenia health care systems: an international comparison using data envelopment analysis
James Weatherall, Jacob Simonsen, Brian L Odlaug
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 12, 2011
Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective
James Weatherall, Nicola Barnes, Chloë Brown, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 29, 2016
Understanding Post-Prandial Hyperglycemia in Patients with Type 1 and Type 2 Diabetes: A Web-based Survey in Germany, the UK, and USA
Meryl Brod, Annie Nikolajsen, James Weatherall, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 23, 2016
The Economic Burden of Post-prandial Hyperglycemia (PPH) Among People with Type 1 and Type 2 Diabetes in Three Countries
Meryl Brod, Annie Nikolajsen, James Weatherall, et al.
Journal of Medical Economics
|
March 22, 2018
Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables
Ws Lane, James Weatherall, Jens Gundgaard, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
December 24, 2011
Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology
Matthew Sperrin, Sarah Thew, James Weatherall, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Scientific American
|
July 16, 2024
Why We Trust Lies
James Weatherall, Cailin O'Connor
Journal of the American Medical Informatics Association : JAMIA
|
March 27, 2018
The Tendril Plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials
Martin Karpefors, James Weatherall
Drug Discovery Today
|
January 10, 2026
Generative AI in pharmaceutical R&D: From large language models to AI agents to regulation
James Weatherall, Chris Meier,
Current Medical Research and Opinion
|
October 22, 2016
Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine
James Weatherall, Lisa Bloudek, Sarah Buchs
Journal of Medical Economics
|
June 24, 2020
The relative efficiency of schizophrenia health care systems: an international comparison using data envelopment analysis
James Weatherall, Jacob Simonsen, Brian L Odlaug
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 12, 2011
Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective
James Weatherall, Nicola Barnes, Chloë Brown, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 29, 2016
Understanding Post-Prandial Hyperglycemia in Patients with Type 1 and Type 2 Diabetes: A Web-based Survey in Germany, the UK, and USA
Meryl Brod, Annie Nikolajsen, James Weatherall, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 23, 2016
The Economic Burden of Post-prandial Hyperglycemia (PPH) Among People with Type 1 and Type 2 Diabetes in Three Countries
Meryl Brod, Annie Nikolajsen, James Weatherall, et al.
Journal of Medical Economics
|
March 22, 2018
Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables
Ws Lane, James Weatherall, Jens Gundgaard, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
December 24, 2011
Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology
Matthew Sperrin, Sarah Thew, James Weatherall, et al.
Page
of 3